VCM
ORGO icon

Versant Capital Management’s Organogenesis Holdings ORGO Stock Holding History

Versant Capital Management’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-355
Closed -$955 – 1797
2022
Q4 		$955 Buy
+355
New +$1.04K ﹤0.01% 1305
2022
Q1 		– Sell
-17
Closed – – 1577
2021
Q4 		$0 Hold
17
– – ﹤0.01% 1548
2021
Q3 		$0 Buy
+17
New +$264 ﹤0.01% 1550

Other funds holding ORGO

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Versant Capital Management's ORGO Position: Q1 2023 in Review

Versant Capital Management sold out of Organogenesis Holdings (ORGO) in Q1 2023, closing a stake of 355 shares — an estimated $955 sold.

Versant Capital Management first reported a position in ORGO in Q3 2021 and held it in 3 quarters. The position peaked at $955 in Q4 2022. 131 funds tracked by Wall St. Rank hold ORGO as of Q1 2023.

  • Versant Capital Management reported no remaining Organogenesis Holdings position as of Q1 2023 after selling out during the quarter.
  • Versant Capital Management sold 355 Organogenesis Holdings shares in Q1 2023, an estimated $955.
  • Versant Capital Management first reported a position in Organogenesis Holdings in Q3 2021 and held it in 3 quarters.
  • Versant Capital Management's Organogenesis Holdings position peaked at $955 in Q4 2022.
  • 131 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2023.

Based on Versant Capital Management's 13F filing for Q1 2023, filed 10 Apr 2023.